Combined OC-LP treatment inhibited the migration and invasion of both HER2-positive breast cancer cell lines, compared to vehicle-treated control cells, as well as OC or LP individual treatments (Figure 5). The gene discussed is ERBB2; the disease is breast carcinoma.